Glutamatergic drugs for schizophrenia: A systematic review and meta-analysis

Schizophrenia Research

Volumn 72, Issue 2-3, 2005, Pages 225-234

  Tuominen, Harri J ^a,b   Tiihonen, Jari ^a,c   Wahlbeck, Kristian ^b,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FIN 00531 Helsinki Finland   (Germany)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d VAASA CENTRAL HOSPITAL   (Finland)

Author keywords

D Cycloserine; D Serine; Glycine; Meta analysis; Schizophrenia; Systematic review

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPAKINE; CYCLOSERINE; DEXTRO SERINE; GLUTAMATE RECEPTOR AGONIST; GLYCINE; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

CALCULATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; HUMAN; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; QUALITY CONTROL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STANDARD; STATISTICAL SIGNIFICANCE; SYMPTOM; SYSTEMATIC REVIEW;

EID: 9244243064     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2004.05.005     Document Type: Article

References (52)

1. D.G. Altman, and J.M. Bland Detecting skewness from summary information BMJ 313 1996 1200
2. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X.S. Hu, A. Cappiello, and J.H. Krystal Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists Arch. Gen. Psychiatry 57 2000 270 276
3. N.C. Andreasen Negative symptoms in schizophrenia. Definition and reliability Arch. Gen. Psychiatry 39 1982 784 788
4. L.S. Benjamin Statistical treatment of the law of initial values (LIV) in autonomic research: a review and recommendation Psychosom. Med. 25 1963 556 566
5. A. Carlsson, N. Waters, S. Waters, and M.L. Carlsson Network interactions in schizophrenia-therapeutic implications Brain Res. Brain Res. Rev. 31 2000 342 349
6. Clarke, M., Oxman, A.D. (Eds.), 2003. Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. http://www.cochrane.dk/cochrane/handbook/handbook.htm (accessed 30 April 2003).
7. S.A. Cohen, and W.E. Muller Effects of piracetam on N-methyl-d-aspartate receptor properties in the aged mouse brain Pharmacology 47 1993 217 222
8. K.L. Davis, R.S. Kahn, G. Ko, and M. Davidson Dopamine in schizophrenia: a review and reconceptualization Am. J. Psychiatry 148 1991 1474 1486
9. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control. Clin. Trials 7 1986 177 188
10. P. Diaz, S. Bhaskara, S.M. Dursun, and J.F. Deakin Double-blind, placebo-controlled, cross-over trial of clozapine plus glycine in refractory schizophrenia: negative results Submitted to J. Psychopharmacol. 2002
11. E. Duncan, S. Szilagyi, M. Schwartz, A. Kunzova, S. Negi, M. Stephanides, D. Bugarski-Kirola, T. Efferen, E. Peselow, S. Gonzenbach, and J. Rotrosen Effects of d-cycloserine on negative symptoms in schizophrenia Presented at Annual Meeting, American Psychiatric Association, Philadelphia 2002
12. M. Egger, S.G. Davey, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
13. J. Endicott, R.L. Spitzer, J.L. Fleiss, and J. Cohen The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance Arch. Gen. Psychiatry 33 1976 766 771
14. A.E. Evins, S.M. Fitzgerald, L. Wine, R. Rosselli, and D.C. Goff Placebo-controlled trial of glycine added to clozapine in schizophrenia Am. J. Psychiatry 157 2000 826 828
15. N.B. Farber, J.W. Newcomer, and J.W. Olney The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease Prog. Brain Res. 116 1998 421 437
16. N.B. Farber, J.W. Newcomer, and J.W. Olney Glycine agonists: what can they teach us about schizophrenia? Arch. Gen. Psychiatry 56 1999 13 17
17. N.B. Farber, S.H. Kim, K. Dikranian, X.P. Jiang, and C. Heinkel Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity Mol. Psychiatry 7 2002 32 43
18. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am. J. Psychiatry 158 2001 1367 1377
19. D.C. Goff, D.C. Henderson, A.E. Evins, and E. Amico A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia Biol. Psychiatry 45 1999 512 514
20. D.C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D.A. Schoenfeld, D.L. Hayden, R. McCarley, and J.T. Coyle A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch. Gen. Psychiatry 56 1999 21 27
21. D.C. Goff, L. Leahy, I. Berman, T. Posever, L. Herz, A.C. Leon, S.A. Johnson, and G. Lynch A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia J. Clin. Psychopharmacol. 21 2001 484 487
22. W. Guy ECDEU Assessment Manual for Psychopharmacology rev. edn. 1976 National Institute of Mental Health Rockville
23. P.D. Harvey, and R.S. Keefe Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment Am. J. Psychiatry 158 2001 176 184
24. U. Heresco-Levy, D.C. Javitt, M. Ermilov, G. Silipo, and J. Shimoni Double-blind, placebo-controlled, crossover trial of d-cycloserine adjuvant therapy for treatment-resistant schizophrenia Int. J. Neuropsychopharmacol. 1 1998 131 135
25. U. Heresco-Levy, D.C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia Arch. Gen. Psychiatry 56 1999 29 36
26. U. Heresco-Levy, M. Ermilov, J. Shimoni, B. Shapira, G. Silipo, and D.C. Javitt Placebo-controlled trial of d-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia Am. J. Psychiatry 159 2002 480 482
27. D.C. Javitt Treatment of negative and cognitive symptoms Curr. Psychiatry Rep. 1 1999 25 30
28. D.C. Javitt, I. Zylberman, S.R. Zukin, U. Heresco-Levy, and J.P. Lindenmayer Amelioration of negative symptoms in schizophrenia by glycine Am. J. Psychiatry 151 1994 1234 1236
29. D.C. Javitt, G. Silipo, A. Cienfuegos, A.M. Shelley, N. Bark, M. Park, J.P. Lindenmayer, R. Suckow, and S.R. Zukin Adjunctive high-dose glycine in the treatment of schizophrenia Int. J. Neuropsychopharmacol. 4 2001 385 391
30. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr. Bull. 13 1987 261 276
31. B. Kirkpatrick, R.W. Buchanan, D.E. Ross, and W.T. Carpenter Jr. A separate disease within the syndrome of schizophrenia Arch. Gen. Psychiatry 58 2001 165 171
32. P.D. Leeson, and L.L. Iversen The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential J. Med. Chem. 37 1994 4053 4067
33. S. Leucht, G. Pitschel-Walz, D. Abraham, and W. Kissling Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials Schizophr. Res. 35 1999 51 68
34. J.P. Lindenmayer, R. Bernstein-Hyman, and S. Grochowski Five-factor model of schizophrenia. Initial validation J. Nerv. Ment. Dis. 182 1994 631 638
35. N. Mantel, and W. Haenszel Statistical aspects of the analysis of data from retrospective studies of disease J. Natl. Cancer Inst. 22 1959 719 748
36. D. Moher, K.F. Schulz, and D. Altman The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials JAMA 285 2001 1987 1991
37. A.A. Noorbala, S. Akhondzadeh, R. Davari-Ashtiani, and H. Amini-Nooshabadi Piracetam in the treatment of schizophrenia: implications for the glutamate hypothesis of schizophrenia J. Clin. Pharm. Ther. 24 1999 369 374
38. J.E. Overall, and D.E. Gorham The brief psychiatric rating scale Psychol. Rep. 10 1961 799 812
39. M. Petticrew Systematic reviews from astronomy to zoology: myths and misconceptions BMJ 322 2001 98 101
40. Potkin, S.G., Costa, J., Roy, S., Sramek, J., Jin, Y., Gulasekaram, B., 1992. Glycine in the treatment of schizophrenia: theory and preliminary results, 179-188.
41. S.G. Potkin, Y. Jin, B.G. Bunney, J. Costa, and B. Gulasekaram Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia Am. J. Psychiatry 156 1999 145 147
42. R.B. Rosse, M. Fay-McCarthy, K. Kendrick, R.E. Davis, and S.I. Deutsch d-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia Clin. Neuropharmacol. 19 1996 444 450
43. K.F. Schulz, and D.A. Grimes Allocation concealment in randomised trials: defending against deciphering Lancet 359 2002 614 618
44. K.F. Schulz, and D.A. Grimes Generation of allocation sequences in randomised trials: chance, not choice Lancet 359 2002 515 519
45. B. Sibbald, and C. Roberts Understanding controlled trials. Crossover trials BMJ 316 1998 1719
46. S.H. Snyder, and P.M. Kim d-Amino acids as putative neurotransmitters: focus on d-serine Neurochem. Res. 25 2000 553 560
47. J.A. Sterne, M. Egger, and G.D. Smith Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis BMJ 323 2001 101 105
48. T.A. Trikalinos, R. Churchill, M. Ferri, S. Leucht, A. Tuunainen, K. Wahlbeck for the EU-PSI project Evolution of randomized evidence over time for outcomes of mental health interventions Accepted for publication in J. Clin. Epidemiol. 2004
49. G. Tsai, P. Yang, L.C. Chung, N. Lange, and J.T. Coyle d-Serine added to antipsychotics for the treatment of schizophrenia Biol. Psychiatry 44 1998 1081 1089
50. G.E. Tsai, P. Yang, L.C. Chung, I.C. Tsai, C.W. Tsai, and J.T. Coyle d-Serine added to clozapine for the treatment of schizophrenia Am. J. Psychiatry 156 1999 1822 1825
51. H.J. Tuominen, K. Wahlbeck, and J. Tiihonen Glutamatergic drugs for schizophrenia (Protocol for a Cochrane Review) The Cochrane Library, Issue 3 2002 Update Software Oxford
52. B.N. van Berckel, C.N. Evenblij, B.J. van Loon, M.F. Maas, M.A. van der Geld, H.J. Wynne, J.M. van Ree, and R.S. Kahn d-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study Neuropsychopharmacology 21 1999 203 210